KPV and the 503A Bulks List: FDA's Review and the July 2026 PCAC Vote

Update (October 2026): At the July 23, 2026 meeting, the Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend adding KPV (free base and acetate) to the 503A Bulks List, going against the FDA staff proposal. The vote is advisory: KPV is not on the 503A Bulks List until FDA completes notice-and-comment rulemaking, which is expected to run into 2027, and FDA can still decline to list it. For current status, see our FDA Peptide Status Tracker.

The Short Answer

At the July 23, 2026 PCAC meeting, FDA proposed that KPV (free base) and KPV acetate not be added to the 503A Bulks List. The nomination (later withdrawn, with FDA proceeding) sought KPV for wound healing and inflammatory conditions. FDA found the characterization, effectiveness, and safety evidence insufficient.

What KPV Is

KPV is a tripeptide — lysine (K), proline (P), and valine (V) — corresponding to the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). It is promoted for its purported anti-inflammatory and wound-healing properties and marketed by compounders as injectable, oral, and topical formulations. For how tripeptides fit the compounding landscape, see the peptide therapy primer.

Characterization: "Not Well-Characterized"

FDA deemed both KPV forms not well-characterized, citing inconsistent naming conventions (INN, IUPAC, USAN) and missing substance-specific quality data. The free base is reported stable up to three years at −20°C; the acetate under refrigeration (2–8°C). But the critical-quality-attribute data needed to reliably establish identity, strength, and purity were not available.

Historical Use: Extent Unknown

FDA found the extent of KPV use in compounding is unknown. Published literature revealed no studies in which compounded KPV products were used in humans, and outsourcing facilities did not report compounding KPV products. Internet marketing exists across injectable, oral, and topical routes, but documented compounding use was not established.

Effectiveness: No Human Data

FDA concluded there is a lack of evidence to evaluate effectiveness for the nominated wound-healing and inflammatory uses. The nomination included no human data, and FDA found none. The agency emphasized that acute and chronic wounds and inflammatory diseases can be serious or life-threatening, and that FDA-approved therapies with established efficacy already exist for wounds and for inflammatory conditions such as psoriasis.

Safety: Mechanistic Hints, No Human Profile

Nonclinical studies suggest KPV may have anti-inflammatory and wound-healing activity in vitro and in vivo — possibly by inhibiting inflammatory cytokines and NF-κB-induced interleukin expression — but FDA noted the molecular targets remain unknown. It found a lack of clinical and nonclinical safety information, and was "particularly concerned" about the absence of any human data by any route, including no data to assess immunogenicity or aggregation.

What It Means for Physicians

KPV was not FDA-approved and remains so. With no USP monograph and no approved-drug status, the 503A Bulks List was the path in question. Review the pillar overview and confirm access with your 503A compounding partner.

Key Takeaways

• FDA is proposing that KPV (free base and acetate) not join the 503A Bulks List.
• No human effectiveness or safety data were identified for the nominated wound-healing and anti-inflammatory uses.
• Mechanistic (cytokine/NF-κB) signals exist, but molecular targets are unknown and immunogenicity is unassessed.
• FDA-approved wound and anti-inflammatory therapies already exist — a factor that weighed against listing.

Frequently Asked Questions

Is KPV banned by the FDA?
No. FDA is proposing that KPV not be added to the 503A Bulks List. It is an advisory-committee proposal, and KPV was never FDA-approved.

What is KPV derived from?
KPV is the lysine-proline-valine tripeptide corresponding to the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH).

What was KPV nominated to treat?
Wound healing and inflammatory conditions. FDA found no human data supporting effectiveness for these uses.

Why did FDA raise safety concerns if KPV is "just" a tripeptide?
Because there is no human safety data by any route, and injectable peptides can pose immunogenicity risk from aggregation and impurities that has not been characterized for KPV.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.